- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.07. | LB Pharmaceuticals launches $150M private placement | 2 | Seeking Alpha | ||
| 29.07. | LB Pharmaceuticals raises $150M in private placement | 3 | Investing.com | ||
| 29.07. | LB Pharmaceuticals Inc: LB Pharmaceuticals Announces $150 Million Private Placement | 1.493 | GlobeNewswire (Europe) | NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact... ► Artikel lesen | |
| 29.07. | LB PHARMACEUTICALS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | Biotech Stocks At 52-Week Highs - INCY Rises With Q2 Results, PLSE, SI, BVS, LBRX | 604 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 28, 2026, driven by key catalysts including positive quarterly results.Incyte Corporation (INCY)Incyte is a... ► Artikel lesen | |
| LB PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 24.07. | H.C. Wainwright bestätigt Kaufempfehlung für LB Pharmaceuticals nach Update zu Schizophrenie-Studie | 1 | Investing.com Deutsch | ||
| 24.07. | H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock | 1 | Investing.com | ||
| 22.07. | LB Pharmaceuticals accelerates schizophrenia trial timeline | 2 | Investing.com | ||
| 22.07. | LB PHARMACEUTICALS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 22.07. | LB Pharmaceuticals: Ergebnisse der Schizophrenie-Studie früher als erwartet | 2 | Investing.com Deutsch | ||
| 22.07. | LB Pharmaceuticals Inc: LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia | 286 | GlobeNewswire (Europe) | NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact... ► Artikel lesen | |
| 20.07. | BMO initiates LB Pharmaceuticals stock at Outperform on drug data | 2 | Investing.com | ||
| 20.07. | LB Pharmaceuticals: BMO startet Coverage mit "Outperform" dank starker Studiendaten | 2 | Investing.com Deutsch | ||
| 10.07. | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 07.07. | Wolfe Research initiates LB Pharmaceuticals stock with outperform rating | 4 | Investing.com | ||
| 30.06. | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations | 471 | GlobeNewswire (Europe) | NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia... ► Artikel lesen | |
| 22.06. | LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright | 2 | Investing.com | ||
| 09.06. | LB PHARMACEUTICALS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | LB Pharmaceuticals Inc: LB Pharmaceuticals to Participate in Upcoming June Investor Events | 1 | GlobeNewswire (USA) | ||
| 26.05. | Clear Street stuft LB Pharmaceuticals mit "Buy" ein und sieht Blockbuster-Potenzial | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 1,505 | +1,01 % | Innocan Pharma Corporation: Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust | Milestone underscores strong consumer confidence, exceptional product quality, and the Company's expanding presence in the U.S. consumer wellness marketHERZLIYA, Israel and CALGARY, Alberta... ► Artikel lesen | |
| JAGUAR HEALTH | 0,959 | +0,40 % | Jaguar Health, Inc.: Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 | As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1 - Jaguar's two commercialized... ► Artikel lesen | |
| KALA BIO | 0,731 | -2,23 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,600 | -3,74 % | Ironwood Pharmaceuticals, Inc. Profit Advances In Q2 | ||
| GALECTIN THERAPEUTICS | 3,020 | +9,42 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet | Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,130 | 0,00 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces $10 Million Private Placement | PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) ("Grace Therapeutics" or "the Company"), a late-stage, biopharma company advancing GTx-104, a clinical-stage... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,880 | -0,04 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,220 | +2,52 % | Morning Market Movers: InMed Pharmaceuticals, INLIF Limited, China SXT Pharmaceuticals, Advanced Biomed See Big Swings | BEIJING (dpa-AFX) - At 8:30 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,590 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an... ► Artikel lesen | |
| MINDWALK | 1,100 | -2,65 % | MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure | Full-year revenue rose 46% to $15.6 million with gross margin expanding to 59%; net loss narrowed by more than half as MindWalk sharpened its focus on the BioIntelligence infrastructure powering... ► Artikel lesen | |
| LIPOCINE | 2,150 | +0,94 % | Lipocine Inc.: Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 | SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,420 | +0,24 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen | |
| HARROW | 33,800 | -3,98 % | Harrow Health Q2 2026 Earnings Preview | ||
| INVENTIVA | 4,190 | -0,12 % | INVENTIVA: Inventiva Announces Preliminary Financial Results for the First Half of 2026 | Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026
Daix (France), New York City (New York, United States), July 30, 2026 - Inventiva (Euronext... ► Artikel lesen | |
| MEDICINOVA | 1,340 | 0,00 % | MediciNova, Inc.: MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients | LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen |
Das Unternehmen LB PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,08 % bei einem Aktienkurs von 47,960 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LB PHARMACEUTICALS INC finden Sie auf Wallstreet Online.